The Weekly Pulse — Edition 39 (June 21, 2026)

Published · Researched 2026-09-22

The week in one paragraph

The number of the week belongs to a cancer trial. The five-year analysis of the Phase 3 CROWN trial — presented at ASCO 2024 and published in the Journal of Clinical Oncology — showed lorlatinib keeping 60% of patients with previously untreated ALK-positive advanced non-small cell lung cancer alive without disease progression at five years, versus just 8% on the prior standard, crizotinib. The hazard ratio of 0.19 translates to an 81% reduction in risk of progression or death, and median progression-free survival hadn't even been reached at five years — the longest ever reported in advanced NSCLC. Metastatic lung cancer used to be measured in months; this one recalibrates what "advanced" can mean for this group.

Rising

Communities are building and reopening at a clip. Johnstown, Pennsylvania completed an $8 million renovation of its Central Park and celebrated with a community- and student-led opening of the renewed public square — a city that has seen hard economic times getting back a piece of itself, with proud residents posting from the reopened park. And in Evans, Georgia, more than 120 volunteers — led by A Soldier's Journey Home, founded by New York City firefighters after 9/11, with nine Chattanooga firefighters among the crews — built a fully accessible, mortgage-free 2,700-square-foot home in 14 days for retired Army Sgt. 1st Class David Mathis, a double amputee injured by an IED in Iraq in 2017. Unveiled May 31, 2025, with the Evans High School Jr. ROTC raising the flag.

Targeted therapy keeps raising the bar. The lorlatinib result sets the benchmark for targeted drugs in solid tumors — 60% versus 8% isn't a nudge, it's a cliff edge between two standards of care.

Rescues that finish. Bowtie, a juvenile green sea turtle treated by Brevard Zoo's Sea Turtle Healing Center after swallowing two fishing hooks, went back to the Atlantic on September 16, 2026 — a completed return after a serious injury, confirmed by the zoo's release announcement and GreaterGood's follow-up report.

Falling

"Lung-cancer survival is stuck." The CROWN five-year data reverses that — three in five progression-free at five years, in a disease once measured in months.

"Nothing gets built anymore." A city square rebuilt and a custom accessible house raised in two weeks by volunteers reverses the default cynicism about civic projects — both completed, both opened, both in use.

Quiet signals

Bowtie's open ocean. The release is documented, but post-release tracking details haven't been published — watching for follow-up on how the turtle fares back in the Atlantic.
The lorlatinib social layer. Oncology press covered CROWN widely, but targeted social searches didn't return direct patient or community posts — the pulse here is media-side, not viral-side, and the tier can't be finalized until that layer is observed. Early, uncertain.
Johnstown's exact celebration date — the $8M renovation and the community/student-led opening are verified via CNHI News, but the celebration date wasn't captured. Still watching.

Scoreboard

N/A — editions written out of sequence; no prior calls to grade.

One line to close

Three in five progression-free at five years, a park back open in Johnstown, a house up in two weeks in Evans, a turtle back in the Atlantic — the week belonged to things built back better than they were.